Company

Smart Matrix Ltd originated – and to this day heavily benefits – from an award-winning, UK-registered charity called The Restoration of Appearance and Function Trust (RAFT). RAFT has a long and successful history in independent medical research. Their work aims to significantly impact the recovery and wellbeing of patients who suffer from major life-changing injuries such as burns and wounds.

Smart Matrix Ltd focuses on commercialising Smart Matrix® the proprietary platform technology developed by RAFT scientists. The first product developed from this Smart Matrix® platform is a scaffold designed to help the body close surgical wounds and regenerate lost skin. Smart Matrix® works by facilitating the growth of skin cells and new blood vessels, critical to healthy healing.

Smart Matrix Ltd has an exclusive, world-wide license to Smart Matrix® and first right of refusal to license other products developed by RAFT that are based on the underlying platform technology.

A service agreement with RAFT gives Smart Matrix Ltd access to RAFT’s staff, infrastructure and network of professional service providers.

Company

Smart Matrix Ltd originated – and to this day heavily benefits – from an award-winning, UK-registered charity called The Restoration of Appearance and Function Trust (RAFT). RAFT has a long and successful history in independent medical research. Their work aims to significantly impact the recovery and wellbeing of patients who suffer from major life-changing injuries such as burns and wounds.

Smart Matrix Ltd focuses on commercialising Smart Matrix® the proprietary platform technology developed by RAFT scientists. The first product developed from this Smart Matrix® platform is a scaffold designed to help the body close surgical wounds and regenerate lost skin. Smart Matrix® works by facilitating the growth of skin cells and new blood vessels, critical to healthy healing.

Smart Matrix Ltd has an exclusive, world-wide license to Smart Matrix® and first right of refusal to license other products developed by RAFT that are based on the underlying platform technology.

A service agreement with RAFT gives Smart Matrix Ltd access to RAFT’s staff, infrastructure and network of professional service providers.

Management and Board

Board and Executive Team

Management and Board

Board and Executive Team

Francis Gugen, FCA (UK) FEI (UK) - Executive Chairman

Francis originally conceived and drove the foundation of Smart Matrix Ltd whilst chairman of RAFT (The Restoration of Appearance and Function Trust), where the original research into Smart Matrix® was carried out.

Francis has a proven track record in building from scratch and chairing successful businesses including at CH4 Ltd, realising investors €224 million or 7.4 times their investment in just over three years; Chrysaor, now one of the largest North Sea producers, acquiring over half of Shell’s UK production for some $3.8 billion; IGas, now one of the largest onshore UK oil and gas players and a big data business in the financial services sector.

CEO experience at Amerada Hess, where initially he was part of a team that took this small player, with a few dozen staff, to become the third largest producer in the UK; with Francis becoming CEO Europe.

Dr Lilian Hook, BA, MA (Cantab), MSc (UCL), PhD (Edinburgh) - Executive Director

Lilian oversees Smart Matrix® product research and development and joined the Smart Matrix Ltd team part-time in 2014 and permanently in August 2017.

20 years’ experience in biomedical research, in both industry and academia. In previous roles, Lilian has focused primarily on the application of stem cells in drug discovery and regenerative medicine.

Lilian holds a PhD in Development Biology from the University of Edinburgh and a degree in Natural Sciences from Cambridge University.

Dr Lilian Hook, BA, MA (Cantab), MSc (UCL), PhD (Edinburgh) - Executive Director

Lilian oversees Smart Matrix® product research and development and joined the Smart Matrix Ltd team part-time in 2014 and permanently in August 2017.

20 years’ experience in biomedical research, in both industry and academia. In previous roles, Lilian has focused primarily on the application of stem cells in drug discovery and regenerative medicine.

Lilian holds a PhD in Development Biology from the University of Edinburgh and a degree in Natural Sciences from Cambridge University.

Jeremy Curnock Cook, BA Hons (Trinity Dublin), MA (Trinity Dublin) - Non-Executive Director

Jeremy has fund management expertise, most recently creating new funds of A$100m, and A$50m in size, targeting the healthcare sector.

Jeremy has been responsible for more than 150 private company investments over the past 30 years, together with the creation and management of specialised healthcare investment funds valued at more than $1 billion. Jeremy is the former head of the life science private equity team at Rothschild Asset Management.

Swen Lorenz - Non-Executive Director

Swen has expertise in fundraising from a broad range of funding sources for private enterprise, charitable organisations and social enterprises.

Successes include $150 million equity raised from 20 financial institutions for a residential property fund in Asia; $5 million for a luxury goods start-up based in Britain; $6 million for the majority take-over and subsequent restructuring of a public shell company in Switzerland; and securing $1.2 million charity funding from one of the ten largest US foundations.

Swen Lorenz - Non-Executive Director

Swen has expertise in fundraising from a broad range of funding sources for private enterprise, charitable organisations and social enterprises.

Successes include $150 million equity raised from 20 financial institutions for a residential property fund in Asia; $5 million for a luxury goods start-up based in Britain; $6 million for the majority take-over and subsequent restructuring of a public shell company in Switzerland; and securing $1.2 million charity funding from one of the ten largest US foundations.

Advisors to the Board

Advisors to the Board

William (Bill) Allan, BDS (Edinburgh), MBA (Cape Town), AMP (Insead) - Senior Advisor to the Board

Bill is an internationally experienced medical devices executive and entrepreneur who has held a number of global leadership positions with large Multinational medical device companies, including Stryker, Smith & Nephew, Angiodynamics, and Orthovita and is currently CEO of SurgaColl Technologies.

In addition, he has been instrumental in the successful transition of three small Medical Device companies to exit.

Bill is a visiting lecturer in Medtech startup ‘route to market strategy’ at the University of Cambridge MBE programme and a mentor at the Judge Business School in Cambridge.

Dr Fulvio Urso-Baiarda, BM, BCH, MA Hons (Oxon), MD (Res), FRCS (Plast) - Consultant Plastic Surgeon and SML Medical Advisor

Fulvio is a Consultant Plastic, Reconstructive and Aesthetic Surgeon with an NHS practice serving the Berkshire region.

Fulvio obtained his medical degree from Oxford University in 1999, a research MD at RAFT and further Plastic Surgery training in Yorkshire, South Australia, London and New York, going on to complete subspecialist fellowship training in Reconstructive Microsurgery at the St Andrews Plastic Surgery Unit in Broomfield.

Fulvio has published extensively in scientific, medical, and plastic surgical journals over the last two decades, in addition to several book chapters and one textbook on Evidence-Based Cosmetic Surgery. He serves on the editorial board of two medical journals and regularly reviews scientific material submitted to six others. His clinical and research interests include body surgery, Botulinum toxin injections (Botox), Breast surgery, Eyelid Surgery, Facelifts, Lip enhancement, Liposuction, Setting back prominent ears.

Dr Fulvio Urso-Baiarda, BM, BCH, MA Hons (Oxon), MD (Res), FRCS (Plast) - Consultant Plastic Surgeon and SML Medical Advisor

Fulvio is a Consultant Plastic, Reconstructive and Aesthetic Surgeon with an NHS practice serving the Berkshire region.

Fulvio obtained his medical degree from Oxford University in 1999, a research MD at RAFT and further Plastic Surgery training in Yorkshire, South Australia, London and New York, going on to complete subspecialist fellowship training in Reconstructive Microsurgery at the St Andrews Plastic Surgery Unit in Broomfield.

Fulvio has published extensively in scientific, medical, and plastic surgical journals over the last two decades, in addition to several book chapters and one textbook on Evidence-Based Cosmetic Surgery. He serves on the editorial board of two medical journals and regularly reviews scientific material submitted to six others. His clinical and research interests include body surgery, Botulinum toxin injections (Botox), Breast surgery, Eyelid Surgery, Facelifts, Lip enhancement, Liposuction, Setting back prominent ears.

Careers

Information about employment opportunities will be posted here when available.

THERE ARE CURRENTLY NO VACANCIES

Careers

Information about employment opportunities will be posted here when available.

THERE ARE CURRENTLY NO VACANCIES